New Zealand markets closed

Vaxart, Inc. (VXRT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.88-0.02 (-0.29%)
At close: 4:00PM EDT
6.88 0.00 (0.00%)
Pre-market: 07:41AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close6.90
Open6.93
Bid0.00 x 3000
Ask6.90 x 4000
Day's range6.86 - 7.06
52-week range3.50 - 24.90
Volume2,831,052
Avg. volume5,962,620
Market cap861.865M
Beta (5Y monthly)0.51
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date09 Nov 2012
1y target estN/A
All
News
  • GlobeNewswire

    SHAREHOLDER ALERT: Morris Kandinov Investigating TSN, VXRT, APYX, and EHTH; Shareholders are Encouraged to Contact the Firm

    SAN DIEGO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Tyson Foods, Inc., Vaxart, Inc., Apyx Medical Corporation, and eHealth, Inc. If you are a current owner of shares of any of these stocks, contact leo@moka.law or call (619) 708-3993. Tyson Foods, Inc. (NYSE: TSN) Shareholder Rights Investigation Morris Kandinov is investigating Tyson Foods, Inc. regarding corporate governance failures, possible bre

  • GlobeNewswire

    Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset

    Milestone payments up to $130 million and royalties for global Vapendavir sales Vapendavir has demonstrated activity against a broad spectrum of enteroviruses SOUTH SAN FRANCISCO, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has signed an exclusive worldwide licensing agreement with Altesa Biosciences, Inc. to allo

  • GlobeNewswire

    Vaxart to Present at the SVB Leerink CybeRx Series: Vaccine Forum

    SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its executive officers, Andrei Floroiu, CEO, and Sean Tucker, CSO, are scheduled to present at the SVB Leerink CybeRx Series: Vaccine Forum on Monday, June 21, 2021 at 1:00 p.m. Eastern Time. SVB Leerink CybeRx Series: Vaccine Forum Date:Monday, June 21